Brain Imaging and Behavior

, Volume 2, Issue 2, pp 94-104

First online:

Atorvastatin Therapy is Associated with Greater and Faster Cerebral Hemodynamic Response

  • Guofan XuAffiliated withWilliam S. Middleton VA HospitalUniversity of Wisconsin Email author 
  • , Michele E. FitzgeraldAffiliated withWilliam S. Middleton VA HospitalUniversity of Wisconsin
  • , Zhifei WenAffiliated withUniversity of Wisconsin
  • , Sean B. FainAffiliated withUniversity of Wisconsin
  • , David C. AlsopAffiliated withBeth Israel Deaconess Medical CenterHarvard Medical School
  • , Timothy CarrollAffiliated withNorthwestern University
  • , Michele L. RiesAffiliated withWilliam S. Middleton VA HospitalUniversity of Wisconsin
  • , Howard A. RowleyAffiliated withUniversity of Wisconsin
  • , Mark A. SagerAffiliated withUniversity of Wisconsin
    • , Sanjay AsthanaAffiliated withWilliam S. Middleton VA HospitalUniversity of Wisconsin
    • , Sterling C. JohnsonAffiliated withWilliam S. Middleton VA HospitalUniversity of Wisconsin
    • , Cynthia M. CarlssonAffiliated withWilliam S. Middleton VA HospitalUniversity of Wisconsin

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Hypercholesterolemia in midlife increases the risk of subsequent cognitive decline, neurovascular disease, and Alzheimer’s disease (AD), and statin use is associated with reduced prevalence of these outcomes. While statins improve vasoreactivity in peripheral arteries and large cerebral arteries, little is known about the effects of statins on cerebral hemodynamic responses and cognition in healthy asymptomatic adults. At the final visit of a 4-month randomized, controlled, double-blind study comparing atorvastatin 40 mg daily to placebo, 16 asymptomatic middle-aged adults (15 had useable data) underwent blood oxygen level dependent (BOLD) functional magnetic resonance imaging (fMRI), arterial spin labeling (ASL) quantitative cerebral blood flow (qCBF), dynamic susceptibility contrast (DSC) and structural imaging of the brain. Using a memory recognition task requiring discrimination of previously viewed (PV) and novel (NV) human faces, fMRI was used to elicit activation from brain regions known to be vulnerable to changes associated with AD. The BOLD signal amplitude (PV > NV) and latency to each stimulus were tested on a voxel basis between the atorvastatin (n = 8) and placebo (n = 7) groups. Persons randomized to atorvastatin not only showed significantly greater BOLD amplitude in the right angular gyrus, left superior parietal lobule, right middle temporal and superior sulcus than the placebo group, but also decreased hemodynamic response latencies in the right middle frontal gyrus, left precentral gyrus, left cuneus and right posterior middle frontal gyrus. However, neither the resting cerebral blood flow (CBF) measured with ASL nor the mean transit time (MTT) of cerebral perfusion calculated from DSC showed differences in these regions in either group. The drug related BOLD differences during memory recognition suggest that atorvastatin may have improved cerebral small vessel vasoreactivity, possibly through an effect on endothelial function. Furthermore, these results suggest that the effect of atorvastatin on the task-induced BOLD signal may not be a simple consequence of baseline flow change.


BOLD Hemodynamic response Arterial spin labeling Dynamic susceptibility contrast Event-related fMRI Alzheimer’s disease